COBIK is aimed to address the most pressing health challenges of the 21st century: antibiotic resistance and emerging viral diseases. Our pipeline is focused on bacteriophage-based solutions and viral vaccines.

We are developing potent antibacterial therapy and nanoparticle vaccine candidate pipeline by applying state-of-the-art bioengineering, genetic and molecular biology tools. Together, we deliver a broad spectrum of next generation therapeutics to combat the emerging threats of infectious disease.


Name Target Stage development pre-clinical clinical trial
COP-01/20 multidrug-resistant S. epidermidis       development
The powerful broad-spectrum phage COP-01/20 cocktail was developed to treat multidrug-resistant Staphylococcus epidermidis infections. Careful COP-01/20 phage selection and purification process provide excellent efficiency and safety profile.
Read more


Name Target Stage development pre-clinical clinical trial
CO-CoVac-01 SARS CoV-2       development
We developed the CO-CoVac-01 vaccine candidate against COVID-19 by using an innovative nanoparticle-based platform. CO-CoVac-01 mimics SARS-CoV-2 particles to deliver safe and robust protection.
Read more

Centre of Excellence for Biosensors, Instrumentation and Process Control

Mirce 21

SI-5270 Ajdovščina